Heart Failure: Novel Therapies, Changing Biomarkers


Learn why NT-proBNP is the biomarker your lab should consider in congestive heart failure

Duration: 20 Minutes

Heart disease is the leading cause of death for both men and women. With the increased use of a novel therapy, ENTRESTO®, are we using the optimal biomarkers to accurately assess the risk and therapeutic response in patients taking this medication?

This promotional educational activity is brought to you by Ortho Clinical Diagnostics and is not certified for Continuing Medical Education (CME). The speakers are presenting on behalf of Ortho Clinical Diagnostics and must present information in accordance with applicable and/or local regulatory country requirements.

About Our Speaker:
About Our Speaker:

Jesse Earl Adams, III, MD

Adult Cardiologist, Director Cardiovascular CareBaptist Health, Louisville, KY